Posted on February 14, 2016 by Amos Adler Being a digital health entrepreneur is an educational experience to say the least. Most lessons are about pain, endurance and learning how to persevere.
TORONTO, Feb. 4, 2016 /CNW/ – A 2014 pilot program for patients with chronic diseases by Green Shield Canada (GSC) and MEMOTEXT Corp. has revealed some new facts about
Posted on January 24, 2016 by Noah Nemoy Advancing the way people interact with their health technology is a pillar of MEMOTEXT’s mission. The greatest part about working on so many different programs for
Posted on January 24, 2016 by Noah Nemoy As a valued MEMOTEXT client we’d like to give you a sneak peek at our latest technological advancement: SAM! SAM is the MEMOTEXT ChatBot for
Looking back on MEMOTEXT’s accomplishments this fall
Posted on December 2, 2015 by Noah Nemoy
This autumn has been an exciting time for MEMOTEXT. In September our Founder and President Amos Adler had the opportunity to be a main stage speaker at Stanford Medicine X 2015. Presenting the abstract: “Using Disparate Data to Personalize Digital Health Behavior Change Interventions” Amos rocked the crowd explaining the MEMOTEXT methodology. He had a fantastic time at the event and the “Cat pics + health data = behavior change” line got a substantial amount of press coverage.
Posted on November 20, 2015 by Amos Adler
Using digital engagement to increase medication adherence is our novel solution to a complex problem. With non-adherence caused by multiple factors unique to each individual patient, a-one-size-fits-all-solution can’t work and won’t work. Instead, at MEMOTEXT we personalize each patient’s support program. By encouraging patient input, adapting to changes in mood and lifestyle, we can develop a medication adherence and support program that works best.
Posted on November 05, 2015 by Noah Nemoy
Medication Compliance is one of the biggest costs to worldwide healthcare systems. 50% of all patients do not take their medication as prescribed and this costs the U.S. healthcare system alone $290 billion per year. That’s a pretty massive figure that can be interpreted in several ways.
We can start by breaking down that $290 billion to show exactly how low compliance rates create such a huge cost:
Posted on October 02, 2015 by Amos Adler
Keywords: #MedXHangover #EmpathyX #MedXorcism, #ActionX
So I’m currently suffering from what’s known as #MedXHangover. Its real, I assure you. Fortunately I don’t have #SyndromeX, a condition associated with attending uncomfortable doctor-patient simulations to simulate uncomfortable doctor-patient interactions.
Posted on September 30, 2015 by Bill Simpson
As the Director of Scientific Development for MEMOTEXT I am honoured to have been invited to speak at this year’s Canadian Psychiatric Association (CPA) annual conference. The 2015 conference runs from Annual Conference October 1st – 3rd in Vancouver, British Columbia. I will be speaking at the “A clinician’s guide to mental health apps.” symposium on Thursday, October 1st at 10:15 PST. The focus of my contribution will be on mHealth and its capacity to affect positive behavioural change.
Abstract: “Using Disparate Data to Personalize Digital Health Behavior Change Interventions” to be presented at conference main stage
Toronto, ON September 16, 2015 – MEMOTEXT is pleased to announce that our Founder and President Amos Adler will be a main stage speaker at Stanford Medicine X 2015. Running from September 23-27 in the heart of Silicon Valley, Medicine X is a catalyst for sharing new ideas on the intersection of healthcare and emerging technologies. Hosted by Stanford University, Medicine X brings together both business and academia for a 4 day conversation on the future of healthcare.
How MEMOTEXT helps you achieve it
Posted on October 13, 2015 by Noah Nemoy
If you’re an American health care provider or are involved in digital health, odds are you’ve been hearing a lot about Meaningful Use (MU) Stage 3 in recent years. But what is it exactly? Why does it matter? And while we’re at it, what is MU Stages 1 and 2?
“The MEMOTEXT Toolkit” walks readers through the problem of patient non-adherence, explaining the methodology behind our digital health interventions
Posted on July 23, 2015 by Noah Nemoy
MEMOTEXT is pleased to unveil “The MEMOTEXT Toolkit” Whitepaper. Authored by MEMOTEXT’s President and Founder Amos Adler M.Sc., Director of Scientific Development Bill Simpson P.hD(c) and Miki Peer P.hD(c), the document explains both the problem of patient adherence and outlines the science behind MEMOTEXT’s methodology.
We use cookies to ensure you get the best experience on our website. By continuing to browse this website, you accept the use of the cookies for the stated purpose. Learn more by reading our privacy policy.
Get updates on new products, projects and stay on top of all things MEMOTEXT.